Trial Profile
A Phase 1, Single-center, Partially Double-blind, Randomized, Single-dose, 3-Period Crossover Study to Assess the Pharmacodynamic Effects of LX4211 and INVOKANA (Canagliflozin) in Healthy Subjects Using Stable Isotope Tracer Methods
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sotagliflozin (Primary) ; Canagliflozin
- Indications Heart failure; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Lexicon Pharmaceuticals
- 14 Dec 2019 Results published in the Journal of Clinical Endocrinology and Metabolism
- 18 Mar 2019 Results presented at the 101st Annual Meeting of the Endocrine Society
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.